For the treatment of infected wounds and abscesses, and infected mouth cavity and dental infections, caused by or associated with Staphylococcus spp., Streptococcus spp. (except Streptococcus faecalis), Bacteroides spp., Fusobacterium necrophorum and Clostridium perfringens. To help provide antimicrobial cover during dental procedures.For the treatment of superficial pyoderma associated with Staphylococcus intermedius.For the treatment of osteomyelitis, caused by Staphylococcus aureus.
Cats: For the treatment of infected wounds and abscesses and infected mouth cavity and dental infections, caused by bacteria sensitive to clindamycin. To help provide antimicrobial cover during dental procedures.Before Antirobe therapy is initiated, the involved pathogens should be identified and sensitivity to clindamycin established.Clindamycin has been shown to have in vitro activity against isolates of the following organisms:Aerobic Gram-positive cocci, including: Staphylococcus intermedius and Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Staphylococcus epidermidis, Streptococcus spp. (except Streptococcus faecalis), Pneumococcus spp.Anaerobic Gram-negative bacilli, including: Bacteroides spp., Fusobacterium spp.Anaerobic Gram-positive non-spore-forming bacilli, including: Propionibacterium spp., Eubacterium spp., Actinomyces spp.Anaerobic and microaerophilic Gram-positive cocci, including: Peptococcus spp., Peptostreptococcus spp., microaerophilic streptococci.Clostridia: Most Cl.perfringens are susceptible; other species such as Cl. sporogenes and Cl. tertium frequently are resistant to clindamycin.Mycoplasma species: Most mycoplasma species are susceptible to clindamycin.